ArticleFrontiers in antibiotics2025
Antibiotic stewardship: what for?
Article in Frontiers in antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic stewardship programs and controlled antibiotic usage have long been considered fundamental strategies in healthcare systems, and these approaches were traditionally viewed as the primary defense against bacterial resistance development. But recent studies reveal a surprising disconnect between antibiotic usage and resistance patterns, with socioeconomic factors showing stronger correlations than clinical drug use. Multiple factors beyond antibiotic consumption now influence resistance patterns, including agricultural antibiotic use, increasing urbanization, and the evolution of mobile genetic elements. Therefore, while antibiotic stewardship remains crucial for preventing side effects and reducing healthcare costs, its role in controlling bacterial resistance requires fundamental reassessment. This understanding necessitates a strategic shift in stewardship programs to focus on more attainable goals, such as patient safety and cost reduction, while developing new, comprehensive approaches to address antibiotic resistance that account for the complex interplay of biological, environmental, and socioeconomic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.